The dynamic single-cell analysis company™
The leader in visual AI for single-cell analysis
Life exists in motion. Cells need to move to fight disease. CellChorus provides high throughput, dynamic analysis of single cells. The company’s TIMING™ platform applies visual AI to evaluate cell activation, killing and movement as a function of time in order to maximize our understanding of cellular function, state and phenotype.
CellChorus is a spinout from the Single Cell Lab at the University of Houston. The company is located in Houston, Texas, and South San Francisco, California. Our customers include top-25 biopharmaceutical companies, small-cap public biopharmaceutical companies, and early stage developers of novel therapies.
The company’s technology is protected in part by issued patents and pending patent applications, including US/10,746,736.
CellChorus has received investment from, won awards from, and participated in accelerators run by the following investors and programs:
Contact the CellChorus team to discuss how we can improve the success of your programs.
Our story
Team
Daniel Meyer
Chief Executive Officer
Daniel Meyer is an early stage entrepreneur and investor with experience across software, hardware and services companies in life sciences and information technology. He was the Chief Operating Officer and a board member of Genospace, an information platform for applied molecular and precision medicine, until its acquisition by HCA Healthcare (NYSE:HCA).
Dan was a member of the venture capital investment teams at Arboretum Ventures and PJC.vc, where he covered investments in life science research products, medical devices, and digital health. He was a member of the healthcare investment banking group at Credit Suisse First Boston. He holds a B.A. in mathematics and economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.
Rebecca Berdeaux, Ph.D.
VP of Science
Dr. Berdeaux is an expert in cell signaling, energy metabolism, and skeletal muscle regeneration. Prior to joining CellChorus, she focused on research and medical education as a tenured Associate Professor of Integrative Biology and Pharmacology with McGovern Medical School at UTHealth Houston, where she retains a faculty position and laboratory. She previously served as the Director of the Graduate Program in Biochemistry and Cell Biology at The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, and as Adjunct Faculty at the Diabetes Research Center in the Department of Medicine at Baylor College of Medicine.
Dr. Berdeaux conducted postdoctoral studies in Molecular Physiology at The Salk Institute for Biological Studies. She earned a PhD in Molecular and Cell Biology from the University of California, Berkeley; and a BS in Biology from the University of Illinois, Urbana-Champaign.
Laurence Cooper, M.D., Ph.D.
Co-founder & Board Chair
Dr. Cooper is the former Chief Executive Officer of Alaunous Therapeutics (NASDAQ: TCRT). Prior to joining Alanous, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies.
Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.
Andrew Last, PhD
Independent Director
Dr. Last serves as Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products with nearly $3 billion in revenue. He previously served as Chief Commercial Officer at Berkeley Lights. Prior to that Dr. Last was Chief Operating Officer at both Intrexon Corporation and Affymetrix. He has also held senior positions with Becton, Dickinson and Company; Applied Biosystems; Incyte Genomics; and Monsanto Company. Dr. Last holds a PhD with Agrochemical Specialization and an MS in Bio-Aeronautics from Cranfield University, UK, as well as a BS from the University of Leicester, UK.
Navin Varadarajan, Ph.D.
Co-founder
Dr. Varadarajan is the M.D. Anderson Professor of Chemical and Biomolecular Engineering at the University of Houston. At the University of Houston, his Single Cell Lab focuses on developing high-throughput screens designed to characterize a wide range of biological functions ranging from the properties of proteins in single cells to antigen mediated cellular cytotoxicity. The development of these assays should serve as versatile platforms for the systemic investigation of B cells and antibodies in autoimmune diseases; characterizing T cell responses in cancer and engineering therapeutic enzymes/antibodies.
Navin is a pioneer of multiple molecular and cellular technologies for immunotherapy. He is an author of 50 papers and seven patent applications, and recipient of multiple young investigator awards.
Navin received a Master's Degree in Organic Chemistry at the India Institute of Science, a Ph.D. in Chemistry at the University of Texas at Austin, and completed Post Doctoral research at the University of Texas and MIT.